Close Menu

Bayer

Kinaxo Biotechnologies and Bayer Vital announced that they are collaborating to identify novel cancer treatment biomarkers.

Dekkers is leaving Thermo Fisher after nine years to become CEO of Bayer.

Celera granted Bayer Schering rights to five cancer-related drug targets while retaining in vitro diagnostic rights.

The molecular diagnostics maker reported an overall 5 percent decline in revenues, but its product sales increased 11 percent for the first quarter.

Although iZumi does not have a license to Kyoto iPSC patents, the collaboration builds upon other seminal iPSC IP it recently licensed from Bayer. The Kyoto deal may also help the company better define iZumi's stake in what is shaping up to be a complicated IP landscape surrounding the technology.

Merck Serono launches venture fund; UK's MedCell and Manchester U partner on stem cell manufacturing; VGX Pharma to study DNA vaccine tech with PATH, UPenn; and more …

William Moffitt signed a three-year contract to remain president and CEO of Nanosphere, while BioTrove's Al Luderer joined Agendia's supervisory board, and more.

BioGenes will supply antibodies for the project, called cNeupro. The deal will enable it to share ownership of the antibodies and pocket royalties on the ones that lead to commercial products.

A company official said Hong Kong may be the best place to conduct the phase I study since data collected may be used in both US and Chinese regulatory filings.

Pages

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.